Please assess the completion status of the following clinical trial:

Trial Title: Combined LDR Boost and HDR Whole Gland

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Adenocarcinoma of the prostate~* Single PIRADS 4 or 5 lesion on multiparametric MRI~* T1c-T2b on rectal exam~* Gleason 3+3 and PSA \< 20ng/mL~* Gleason 3+4 and PSA \<10ng/mL~* Less than 50% of the cores positive in an untargeted prostate biopsy.~* Prostate volume \< 60 cc~Exclusion Criteria:~* Incapable or ineligible for MRI imaging~* Previous trans-urethral resection of prostate (TURP)~* Previous or current use of androgen deprivation~* Baseline International Prostate Symptom Score (IPSS) \> 15~* Evidence of distant or nodal metastasis~* Disease that contraindicates treatment with radiation (e.g connective tissue disease)~* Unsuitable for anesthesia due to comorbidity

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDR/HDR (Type: EXPERIMENTAL): MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).